Open Label Macugen for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT00406107 Phase 4 COMPLETED Results posted

The purpose of this study is to evaluate the effect of intravitreal injections of Macugen every 6 weeks for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO). We hypothesize that macular edema secondary to BRVO is mediated by VEGF 165 and that chronic suppression of VEGF 165 will successfully treat BRVO related macular edema.

Details

Lead sponsor	Palmetto Retina Center, LLC
Phase	Phase 4
Status	COMPLETED
Enrolment	20
Start date	2006-01
Completion	2008-04

Conditions

• Branch Retinal Vein Occlusion

Interventions

• pegaptanib sodium (Macugen)

Primary outcomes

• Change in ETDRS Best Corrected Visual Acuity From Baseline at 54 Weeks — 54 Weeks

Countries

United States